

SUBSTITUTED CATHINONES TRADE NAME AND CHEMICAL COMPOUND CHART

This project was supported by Cooperative Agreement No. 2012-DC-BX-K002 awarded by the Bureau of Justice Assistance. The Bureau of Justice Assistance is a component of the Office of Justice Programs, which also includes the Bureau of Justice Statistics, the National Institute of Justice, the office of Juvenile Justice and Delinquency Prevention, the office for Victims of Crime, the Community Capacity Development Office, and the Office of Sex Offender Sentencing, Monitoring, Apprehending, Registering, and Tracking. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the U.S. Department of Justice.

The following chart may not include all trade or other names for the designated substances. It also may not include all variations in the chemical composition of the substance.

© 2013 Research is current as of January 24, 2013. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

Trade or Other Name	Chemical Compound
2-diphenylmethylpyrrolidine	2-benzylhydrylpyrrolidin; OR (S)-(-)-2-
	(diphenylmethyl)pyrrolidine; OR (S)-2-
	diphenylmethylpyrrolidine; OR (2S)-2-
	benzylhydrylpyrrolidine; OR (2S)diphenylmethylpyrrolidine
2-DPMP	desoxypipradrol; OR diphenylprolinol; OR 2-
	diphenylmethylpiperidine; OR 2-benzhydrylpiperidine
2-FMC	2-fluoromethcathinone
3,4-DMMC	3,4-dimethylmethcathinone
3-FMC	3-fluoromethcathinone
4-EMC	4-ethylmethcathinone; OR 4-ethyl-methcathinone
4-FMC, Flephedrone	4-fluoromethcathinone
4-MBC, Benzedrone	(±)-1-(4-methylphenyl)-2-(benzylamino)propan-1-one; OR 4-
	methyl-N-benzylcathinone; OR N-benzyl-4-methylcathinone;
	OR 1-(4-methylphenyl)-2-benzyla-minopropan-1-one
4-MEC	4-methyl-N-ethylcathinone; OR 4-methylethcathinone; OR
	para-methyl-N-ethylcathinone; OR para-methylethcathinone;
	OR 4-methyl-ethylcathinone
4-MeMABP	4-methylbuphedrone; OR (2-Methylamino-1-(4-
	methylphenyl)butan-1-one); OR 2-methylamino-1-(4-
	methylphenyl)butan-1-one
a-PBP, alpha-PBP	alpha-Pyrrolidinobutiophenone; OR a-
	Pyrrolidinobutiophenone; OR (RS)1-phenyl-2-(1-
	pyrrolidinyl)-1-pentanone
a-PPP, alpha-PPP	alpha-pyrrolidinopropiophenone; OR a-
	pyrrolidinopropiophenone
a-PVP, alpha-PVP	alpha-Pyrrolidinopentiophenone; OR a-
	Pyrrolidinopentiophenone; OR 1-phenyl-2-(1-pyrrolidinyl)-1-
	pentanone; OR alpha-pyrrolidinovalerophenone; OR a-
	pyrrolidinovalerophenone
Amfepramone,	(RS)-2-diethylamino-1-phenylpropan-1-one
diethylcathinone, diethylpropion	
BZ-6378 (sometimes used as	4-methylephedrone
another name for mephedrone)	
Buphedrone	a-methylamino-butyrophenone; OR 2-(methylamino)-1-
	phenylbutan-1-one; OR alpha-methylamino-butyrophenone
Butylone, bk-MBDB	beta-Keto-N-methylbenzodioxolylpropylamine; OR beta-
	Keto-N-methyl-3,4-benzodioxyolybutanamine
BZP	benzylpiperazine; OR N-benzylpiperazine
D2PM	diphenyl-2-pyrrolidinyl-methanol
Dimethocaine	(3-diethylamino-2,2-dimethylpropyl)-4-aminobenzoate
DMBDB, bk-DMBDB,	1-(Benzo[d][1,3]dioxol-5-yl)-2-(dimethylamino)butan-1-one
dibutylone	

^{© 2013} Research is current as of January 24, 2013. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

DMEC	dimethylethcathinone
DMMC	dimethylmethcathinone
Ephedrone (sometimes used as	2-(methylamino)-1-phenylpropan-1-one; OR 2-methylamino-
another name for	1-phenylpropan-1-one
methcathinone)	
Ethcathinone	2-ethylamino-1-phenyl-propan-1-one
Ethylethcathinone	
Ethylmethcathinone	
Ethylone	3,4-methylenedioxy-N-ethylcathinone; OR 3,4-
	methylenedioxyethylcathinone; OR 3,4-methylenedioxy-
	ethylcathinone; OR 3,4-methylenedioxyethcathinone
Eutylone	beta-Keto-Ethylbenziodioxolylbutanamine
Fluorococaine	
Fluoroethcathinone	
Fluoroioscathinone	
HMMC	3-methoxymethcathinone
Isopentedrone	
MaPPP, 4-MePPP, MPPP	4-methyl-alpha-pyrrolidinopropiophenone; OR 4-methyl-a-
	pyrrolidinopropiophenone; OR
	methylpyrrolidinopropiophenone; OR Methyl-
	pyrrolindinopropiophenone
MBP	Methylbuphedrone
MBZP	1-methyl-4-benzylpiperazine
MDAI	methylenedioxy-aminoindane; OR 5,6-methylenedioxy-2-
	aminoindane
MDAT	6,7-methylenedioxy-2-aminotetralin
MDDMA	Dimethylone
MDMC	Methylenedioxymethcathinone
MDPBP	3,4-methylenedioxy-alpha-pyrrolidinobutiophenone; OR 3,4-
	methylenedioxy-a-pyrrolidinobutiophenone
MDPPP	3,4-methylenedioxy-a-pyrrolidinopropiophenone; OR (RS)-1-
	(3,4-methylenedioxyphenyl)-2-(1-pyrrolidinyl)-1-propanone;
	OR 3,4-methylenedioxy-alpha-pyrrolidinopropiophenone
MDPV, MDPK	3,4-methylenedioxypyrovalerone; OR
	methylenedioxypyrovalerone
MEC	Methylethcathinone
Mephedrone, 4-MMC	4-methylmethcathinone; OR 4-methylephedrone; OR (RS)-2-
	methylamino-1-(4-methylphenyl)propan-1-one
Metamfepramone, N,N-DMMC	N,N-dimethylcathinone
Methedrone, Bk-PMMA,	para-methoxymethcathinone; OR 4-methoxymethcathinone;
PMMC	OR methoxyphedrine; OR (RS)-1-(4-methoxyphenyl)-2-
	(methylamino)propan-1-one
Methylone, bk-MDMA, MDMC	3,4-methylenedioxy-N-methylcathinone; OR 3,4-

^{© 2013} Research is current as of January 24, 2013. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

	methylenedioxymethcathinone; OR 3,4-
	methylenedioxymethylcathinone
MOMC	Methoxymethcathinone
MOPPP	4-methoxy-alpha-pyrrolidinopropiophenone; OR 4-methoxy-
	a-pyrrolidinopropiophenone
MPBP	4-methyl-alpha-pyrrolidinobutyrophenone; OR 4-methyl-a-
	pyrrolidinobutryophenone; OR 4-methyl-alpha-
	pyrrolidinobutiophenone; OR 4-methyl-a-
	pyrrolidinobutiophenone
N-ethyl-N-methylcathinone	
NEB	N-ethylbuphedrone; OR 2-(Ethylamino)-1-phenylbutan-1-one
NRG-1, Naphyrone	naphthylpyrovalerone
NRG-2	
Pentedrone	a-methylamino-Valerophenone; OR 2-(methylamino)-1-
	phenyl-1-pentanone; OR 2-methylamino-1-phenyl-1-
	pentanone
Pentylone	beta-Keto-N-methylbenzodioxolylpentanamine; OR beta-
	keto-ethylbenzodioxolylpentanamine
ACMD Suggested Generic	Any compound (not being bupropion) structurally derived
Language	from 2-amino-1-phenyl-1-propanone by modification in any
	of the following ways, that is to say,
	(i) by substitution in the phenyl ring to any extent with alkyl,
	alkoxy, alkylenedioxy, haloalkyl or halide substituents,
	whether or not further substituted in the phenyl ring by one or
	more other univalent substituents;
	(ii) by substitution at the 3-position with an alkyl substituent;
	(iii) by substitution at the nitrogen atom with alkyl or dialkyl
	groups, or by inclusion of the nitrogen atom in a cyclic
	structure.

^{© 2013} Research is current as of January 24, 2013. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.